VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with one institutional investor for an offering of shares of common stock with gross proceeds of approximately $1.51 million in a registered direct offering. The closing of the offering is expected to take place on or about May 3, 2017, subject to the satisfaction of customary closing conditions.
In connection with the offering, the CEL-SCI will issue approximately 13,199,000 registered shares of common stock at a purchase price of $0.115 per share. Concurrently in a private placement, the Company will issue warrants to purchase up to 9,899,250 shares of its common stock. For each share of common stock purchased in the registered direct offering, such investor in the private placement will receive from the CEL-SCI an unregistered warrant to purchase 0.75 share of common stock. The warrants have an exercise price of $0.1214 per share, will be exercisable upon the 6 month anniversary of the issue date, and will expire five and a half years from the issue date.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, is acting as the exclusive placement agent in connection with the offering.
CEL-SCI intends to use the net proceeds from the offering for the Phase 3 clinical study and general corporate purposes.
About CEL-SCI Corporation
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. Subject to the partial clinical hold, the study was designed with the objective that, if the study endpoint, which is an improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care (SOC) as compared to subjects treated with the current SOC only, is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase 1 trial of the former indication (treatment of cervical dysplasia in HIV/HPV co-infected women) has been completed at the University of Maryland. The latter indication (treatment of peri-anal warts in HIV/HPV co-infected men and women) is being studied in a Phase 1 trial at the University of California, San Francisco. CEL-SCI has patents on Multikine from the US, Europe, China, and Japan.

